Verekitug Clinical Trials (2026): 4 Studies for Severe Asthma & Chronic Obstructive Pulmonary Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 Verekitug clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Severe Asthma & Chronic Obstructive Pulmonary Disease) and 1,622 total planned enrollment. Most recent activity: NCT06981078 (Jul 2028).
Verekitug clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | Total |
|---|---|---|---|
| P2 | 2 | 2 | 4 |
Verekitug clinical trials by indication
Severe Asthma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06966479 | UPB-101 | P2 | active not recruiting | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) |
| NCT06196879 | UPB-101 | P2 | completed | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) |
Chronic Obstructive Pulmonary Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06981078 | — | P2 | active not recruiting | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD |
Chronic Rhinosinusitis With Nasal Polyps (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06164704 | VIBRANT | P2 | completed | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps |
Verekitug pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| UPB-101 | NCT06966479 | P2 | active not recruiting | Severe Asthma | 396 | — |
| UPB-101 | NCT06196879 | P2 | completed | Severe Asthma | 479 | — |
| VIBRANT | NCT06164704 | P2 | completed | Chronic Rhinosinusitis With Nasal Polyps | 81 | — |
All Verekitug trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06981078 | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | P2 | active not recruiting | 666 | Upstream Bio Inc. | Jul 2025 | |
| NCT06966479 | UPB-101 | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | P2 | active not recruiting | 396 | Upstream Bio Inc. | May 2025 |
| NCT06196879 | UPB-101 | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) | P2 | completed | 479 | Upstream Bio Inc. | Feb 2024 |
| NCT06164704 | VIBRANT | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps | P2 | completed | 81 | Upstream Bio Inc. | Dec 2023 |
Verekitug clinical trials: frequently asked questions
- How many Verekitug clinical trials are there?
- 4 Verekitug clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
- Are Verekitug clinical trials recruiting in 2026?
- No active Verekitug trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Verekitug being studied for?
- Verekitug is being studied for Severe Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps. The trials are grouped by indication on this page.
- What phase is Verekitug in?
- Verekitug clinical trials span 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Verekitug clinical trials?
- The lead sponsor across the most Verekitug trials is Upstream Bio Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Verekitugas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: